Status:
WITHDRAWN
The Avastin vs Visudyne for Neovascular AMD Study
Lead Sponsor:
St. Erik Eye Hospital
Conditions:
Age-related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The object of the study is to compare the treatment effect of bevacizumab (Avastin), an antibody targeting vascular endothelial growth factor, with verteporfin photodynamic therapy (PDT) for patients ...
Detailed Description
Neovascular age-related macular degeneration (AMD) is caused by an ingrowth of pathological vessels under the macula. Experimental studies have demonstrated that vascular endothelial growth factor (VE...
Eligibility Criteria
Inclusion
- patients with subfoveal neovascular AMD with either classic/predominantly classic or small occult lesions
- visual acuity \>=0.1
Exclusion
- patients with subfoveal neovascular AMD with minimally classic lesions or large occult lesions
- subfoveal hemorrhage (\>1DA) or fibrosis
- patients previously treated for neovascular AMD in the study eye
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00390026
Start Date
November 1 2006
End Date
November 1 2008
Last Update
January 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
S:t Eriks Eye Hospital
Stockholm, Sweden, SE-11282